
DATA SHOWS HALF OF ALL SPENDING ON BRAND MEDICINES IS RETAINED BY MANUFACTURER
Last year, PILMA in collaboration with union health care and benefits expert Randy DeFrehn released a report titled “An Understanding and Implications of the Cost Drivers in the Drug Supply Chain.”